'Without explanation beyond encouraging “an authentic dialogue,” Facebook has reversed a policy that allowed pharmaceutical companies proactively moderate wall comments, deciding which they would move forward and which they would delete.
As a result, several pharmas—Astra Zeneca, for example, and Bayer. Others, like Amgen, suspended their plans to introduce pages. The change does not apply to product-specific pages, but it does affect pages dedicated to conditions. In other words, a company making a diabetic drug can still proactively moderate comments on the page for the drug, but not on its page about “Healthy Living with Diabetes.”'